Tokyo Tape
Sign in
← ASKA Pharmaceutical Holdings

Annual report

4886.TEDINET S100VZL4
Period2024-04-01 → 2025-03-31
Filed2025-06-20
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 122
MetricValuePeriodScopeSource row
Revenue¥64.1bn2024-04-01 → 2025-03-31Cons.Net sales
Revenue¥62.8bn2023-04-01 → 2024-03-31Cons.Net sales
Revenue¥60.5bn2022-04-01 → 2023-03-31dCons.Net sales (5-year summary)
Revenue¥56.6bn2021-04-01 → 2022-03-31dCons.Net sales (5-year summary)
Operating income¥5.3bn2024-04-01 → 2025-03-31Cons.Operating income
Operating income¥6.5bn2023-04-01 → 2024-03-31Cons.Operating income
Ordinary income¥5.1bn2024-04-01 → 2025-03-31Cons.Ordinary income
Ordinary income¥6.5bn2023-04-01 → 2024-03-31Cons.Ordinary income
Ordinary income¥5.2bn2022-04-01 → 2023-03-31dCons.Ordinary income loss (5-year summary)
Ordinary income¥4.9bn2021-04-01 → 2022-03-31dCons.Ordinary income loss (5-year summary)
Profit before tax¥6.2bn2024-04-01 → 2025-03-31Cons.Income before income taxes
Profit before tax¥9.9bn2023-04-01 → 2024-03-31Cons.Income before income taxes
Net income (owners)¥5.1bn2024-04-01 → 2025-03-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥7.5bn2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥4.2bn2022-04-01 → 2023-03-31dCons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥4.3bn2021-04-01 → 2022-03-31dCons.Profit loss attributable to owners of parent (5-year summary)
Net income¥5.1bn2024-04-01 → 2025-03-31Cons.Profit loss
Net income¥7.5bn2023-04-01 → 2024-03-31Cons.Profit loss
Total assets¥100.5bnat 2025-03-31Cons.Assets
Total assets¥90.7bnat 2024-03-31Cons.Assets
Total assets¥87.1bnat 2023-03-31dCons.Total assets (5-year summary)
Total assets¥83.3bnat 2022-03-31dCons.Total assets (5-year summary)
Total liabilities¥31.3bnat 2025-03-31Cons.Liabilities
Total liabilities¥28.8bnat 2024-03-31Cons.Liabilities
Net assets / equity¥69.2bnat 2025-03-31Cons.Net assets
Net assets / equity¥61.9bnat 2024-03-31Cons.Net assets
Net assets / equity¥54.5bnat 2023-03-31dCons.Net assets
Net assets / equity¥48.9bnat 2022-03-31dCons.Net assets (5-year summary)
Cash and deposits¥10.6bnat 2025-03-31Cons.Cash and deposits
Cash and deposits¥13.7bnat 2024-03-31Cons.Cash and deposits
Cash & equivalents¥10.6bnat 2025-03-31Cons.Cash and cash equivalents
Cash & equivalents¥16.7bnat 2024-03-31Cons.Cash and cash equivalents
Cash & equivalents¥17.5bnat 2023-03-31dCons.Cash and cash equivalents
Cash & equivalents¥17.1bnat 2022-03-31dCons.Cash and cash equivalents (5-year summary)
Operating cash flow¥2.5bn2024-04-01 → 2025-03-31Cons.Net cash provided by used in operating activities
Operating cash flow¥1.5bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in operating activities
Operating cash flow¥3.4bn2022-04-01 → 2023-03-31dCons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥2.8bn2021-04-01 → 2022-03-31dCons.Net cash provided by used in operating activities (5-year summary)
Investing cash flow−¥6.1bn2024-04-01 → 2025-03-31Cons.Net cash provided by used in investment activities
Investing cash flow¥1.7bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in investment activities
Investing cash flow−¥1.1bn2022-04-01 → 2023-03-31dCons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow¥6.7bn2021-04-01 → 2022-03-31dCons.Net cash provided by used in investing activities (5-year summary)
Financing cash flow−¥3.0bn2024-04-01 → 2025-03-31Cons.Net cash provided by used in financing activities
Financing cash flow−¥3.9bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in financing activities
Financing cash flow−¥1.8bn2022-04-01 → 2023-03-31dCons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥3.0bn2021-04-01 → 2022-03-31dCons.Net cash provided by used in financing activities (5-year summary)
EPS (basic)¥179.952024-04-01 → 2025-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥266.512023-04-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥150.082022-04-01 → 2023-03-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥151.222021-04-01 → 2022-03-31dCons.Basic earnings loss per share (5-year summary)
Net assets per share¥2,302.61at 2025-03-31Cons.Net assets per share (5-year summary)
Net assets per share¥2,186.1at 2024-03-31Cons.Net assets per share (5-year summary)
Net assets per share¥1,928.14at 2023-03-31dCons.Net assets per share (5-year summary)
Net assets per share¥1,734.8at 2022-03-31dCons.Net assets per share (5-year summary)
Equity ratio65.0%at 2025-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio68.3%at 2024-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio62.6%at 2023-03-31dCons.Equity to asset ratio (5-year summary)
Equity ratio58.7%at 2022-03-31dCons.Equity to asset ratio (5-year summary)
ROE8.0%2024-04-01 → 2025-03-31Cons.Rate of return on equity (5-year summary)
ROE13.0%2023-04-01 → 2024-03-31Cons.Rate of return on equity (5-year summary)
ROE8.2%2022-04-01 → 2023-03-31dCons.Rate of return on equity (5-year summary)
ROE8.8%2021-04-01 → 2022-03-31dCons.Rate of return on equity (5-year summary)
Employees1,632at 2025-03-31Cons.Number of employees
Employees762at 2024-03-31Cons.Number of employees
Employees747at 2023-03-31dCons.Number of employees
Employees777at 2022-03-31dCons.Number of employees
Revenue¥4.5bn2024-04-01 → 2025-03-31StandaloneOperating revenue1
Revenue¥3.7bn2023-04-01 → 2024-03-31StandaloneOperating revenue1
Revenue¥1.7bn2022-04-01 → 2023-03-31dStandaloneOperating revenue1 (5-year summary)
Revenue¥1.4bn2021-04-01 → 2022-03-31dStandaloneOperating revenue1 (5-year summary)
Operating income¥3.2bn2024-04-01 → 2025-03-31StandaloneOperating income
Operating income¥2.5bn2023-04-01 → 2024-03-31StandaloneOperating income
Ordinary income¥3.2bn2024-04-01 → 2025-03-31StandaloneOrdinary income
Ordinary income¥2.5bn2023-04-01 → 2024-03-31StandaloneOrdinary income
Ordinary income¥603m2022-04-01 → 2023-03-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥717m2021-04-01 → 2022-03-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax¥3.2bn2024-04-01 → 2025-03-31StandaloneIncome before income taxes
Profit before tax¥2.5bn2023-04-01 → 2024-03-31StandaloneIncome before income taxes
Net income¥3.2bn2024-04-01 → 2025-03-31StandaloneProfit loss
Net income¥2.5bn2023-04-01 → 2024-03-31StandaloneProfit loss
Net income¥591m2022-04-01 → 2023-03-31dStandaloneNet income loss (5-year summary)
Net income¥682m2021-04-01 → 2022-03-31dStandaloneNet income loss (5-year summary)
Total assets¥48.3bnat 2025-03-31StandaloneAssets
Total assets¥43.2bnat 2024-03-31StandaloneAssets
Total assets¥41.6bnat 2023-03-31dStandaloneTotal assets (5-year summary)
Total assets¥41.3bnat 2022-03-31dStandaloneTotal assets (5-year summary)
Total liabilities¥3.6bnat 2025-03-31StandaloneLiabilities
Total liabilities¥565mat 2024-03-31StandaloneLiabilities
Net assets / equity¥44.6bnat 2025-03-31StandaloneNet assets
Net assets / equity¥42.7bnat 2024-03-31StandaloneNet assets
Net assets / equity¥40.9bnat 2023-03-31dStandaloneNet assets
Net assets / equity¥40.7bnat 2022-03-31dStandaloneNet assets (5-year summary)
Cash and deposits¥5.4bnat 2025-03-31StandaloneCash and deposits
Cash and deposits¥2.2bnat 2024-03-31StandaloneCash and deposits
EPS (basic)¥111.572024-04-01 → 2025-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥87.12023-04-01 → 2024-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥20.952022-04-01 → 2023-03-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥23.792021-04-01 → 2022-03-31dStandaloneBasic earnings loss per share (5-year summary)
Dividend per share¥552024-04-01 → 2025-03-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥402023-04-01 → 2024-03-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥162022-04-01 → 2023-03-31dStandaloneDividend paid per share (5-year summary)
Dividend per share¥152021-04-01 → 2022-03-31dStandaloneDividend paid per share (5-year summary)
Net assets per share¥1,574.11at 2025-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥1,506.47at 2024-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥1,447.55at 2023-03-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥1,443.94at 2022-03-31dStandaloneNet assets per share (5-year summary)
Equity ratio92.5%at 2025-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio98.7%at 2024-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio98.5%at 2023-03-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio98.5%at 2022-03-31dStandaloneEquity to asset ratio (5-year summary)
ROE7.2%2024-04-01 → 2025-03-31StandaloneRate of return on equity (5-year summary)
ROE5.9%2023-04-01 → 2024-03-31StandaloneRate of return on equity (5-year summary)
ROE1.5%2022-04-01 → 2023-03-31dStandaloneRate of return on equity (5-year summary)
ROE1.7%2021-04-01 → 2022-03-31dStandaloneRate of return on equity (5-year summary)
Shares issued28,763,199at 2025-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued30,563,199at 2024-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued30,563,199at 2023-03-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued30,563,199at 2022-03-31dStandaloneTotal number of issued shares (5-year summary)
Employees80at 2025-03-31StandaloneNumber of employees
Employees75at 2024-03-31StandaloneNumber of employees
Employees79at 2023-03-31dStandaloneNumber of employees
Employees74at 2022-03-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 57
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsemployeesat 2025-03-3116 pure
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2024-04-01 → 2025-03-31¥325m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2024-04-01 → 2025-03-31¥237m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2024-04-01 → 2025-03-31¥88m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment assetsat 2025-03-31¥51m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2024-04-01 → 2025-03-31¥2m
Reconciling Itemsreconcilingdepreciation2024-04-01 → 2025-03-31¥192m
Reconciling Itemsreconcilingrevenue2024-04-01 → 2025-03-31−¥88m
Reconciling Itemsreconcilingrevenue intersegment2024-04-01 → 2025-03-31−¥88m
Reconciling Itemsreconcilingsegment assetsat 2025-03-31¥31.9bn
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2025-03-31−¥1.3bn
Animal Health Businessreportable segmentdepreciation2024-04-01 → 2025-03-31¥3m
Animal Health Businessreportable segmentemployeesat 2025-03-3132 pure
Animal Health Businessreportable segmentrevenue2024-04-01 → 2025-03-31¥7.2bn
Animal Health Businessreportable segmentrevenue external2024-04-01 → 2025-03-31¥7.2bn
Animal Health Businessreportable segmentsegment assetsat 2025-03-31¥4.2bn
Animal Health Businessreportable segmentsegment profit2024-04-01 → 2025-03-31¥300m
Oversea Businessreportable segmentemployeesat 2025-03-31857 pure
Oversea Businessreportable segmentsegment assetsat 2025-03-31¥14.9bn
Pharmaceutical Businessreportable segmentdepreciation2024-04-01 → 2025-03-31¥1.7bn
Pharmaceutical Businessreportable segmentemployeesat 2025-03-31635 pure
Pharmaceutical Businessreportable segmentrevenue2024-04-01 → 2025-03-31¥56.7bn
Pharmaceutical Businessreportable segmentrevenue external2024-04-01 → 2025-03-31¥56.7bn
Pharmaceutical Businessreportable segmentsegment assetsat 2025-03-31¥49.6bn
Pharmaceutical Businessreportable segmentsegment profit2024-04-01 → 2025-03-31¥6.3bn
Total Of Reportable Segments And Otherssegment totaldepreciation2024-04-01 → 2025-03-31¥1.7bn
Total Of Reportable Segments And Otherssegment totalrevenue2024-04-01 → 2025-03-31¥64.2bn
Total Of Reportable Segments And Otherssegment totalrevenue external2024-04-01 → 2025-03-31¥64.1bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2024-04-01 → 2025-03-31¥88m
Total Of Reportable Segments And Otherssegment totalsegment assetsat 2025-03-31¥68.7bn
Total Of Reportable Segments And Otherssegment totalsegment profit2024-04-01 → 2025-03-31¥6.7bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-04-01 → 2024-03-31¥226m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-04-01 → 2024-03-31¥162m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-04-01 → 2024-03-31¥64m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment assetsat 2024-03-31¥39m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-04-01 → 2024-03-31−¥125m
Reconciling Itemsreconcilingdepreciation2023-04-01 → 2024-03-31¥201m
Reconciling Itemsreconcilingrevenue2023-04-01 → 2024-03-31−¥64m
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2024-03-31−¥64m
Reconciling Itemsreconcilingsegment assetsat 2024-03-31¥42.2bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2024-03-31−¥1.2bn
Animal Health Businessreportable segmentdepreciation2023-04-01 → 2024-03-31¥4m
Animal Health Businessreportable segmentrevenue2023-04-01 → 2024-03-31¥6.7bn
Animal Health Businessreportable segmentrevenue external2023-04-01 → 2024-03-31¥6.7bn
Animal Health Businessreportable segmentsegment assetsat 2024-03-31¥3.5bn
Animal Health Businessreportable segmentsegment profit2023-04-01 → 2024-03-31¥195m
Pharmaceutical Businessreportable segmentdepreciation2023-04-01 → 2024-03-31¥2.2bn
Pharmaceutical Businessreportable segmentrevenue2023-04-01 → 2024-03-31¥56.0bn
Pharmaceutical Businessreportable segmentrevenue external2023-04-01 → 2024-03-31¥56.0bn
Pharmaceutical Businessreportable segmentsegment assetsat 2024-03-31¥45.0bn
Pharmaceutical Businessreportable segmentsegment profit2023-04-01 → 2024-03-31¥7.6bn
Total Of Reportable Segments And Otherssegment totaldepreciation2023-04-01 → 2024-03-31¥2.2bn
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2024-03-31¥62.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2024-03-31¥62.8bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2024-03-31¥64m
Total Of Reportable Segments And Otherssegment totalsegment assetsat 2024-03-31¥48.6bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2024-03-31¥7.7bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 1,602
ItemContextValueUnit
Non operating expensesCurrentYearDuration622000000JPY
Ordinary incomePrior1YearDuration6522000000JPY
Ordinary incomeCurrentYearDuration5107000000JPY
Subsidiary related profit and loss eiPrior1YearDuration－JPY
Subsidiary related profit and loss eiCurrentYearDuration1257000000JPY
Gain on sales of investment securities eiPrior1YearDuration3340000000JPY
Gain on sales of investment securities eiCurrentYearDuration127000000JPY
Extraordinary incomePrior1YearDuration3340000000JPY
Extraordinary incomeCurrentYearDuration1384000000JPY
Impairment loss elPrior1YearDuration－JPY
Impairment loss elCurrentYearDuration300000000JPY
Extraordinary lossPrior1YearDuration－JPY
Extraordinary lossCurrentYearDuration300000000JPY
Income before income taxesPrior1YearDuration9862000000JPY
Income before income taxesCurrentYearDuration6192000000JPY
Income taxes currentPrior1YearDuration3514000000JPY
Income taxes currentCurrentYearDuration750000000JPY
Income taxes deferredPrior1YearDuration-1197000000JPY
Income taxes deferredCurrentYearDuration341000000JPY
Income taxesPrior1YearDuration2316000000JPY
Income taxesCurrentYearDuration1091000000JPY
Profit lossPrior1YearDuration7545000000JPY
Profit lossCurrentYearDuration5101000000JPY
Profit loss attributable to owners of parentPrior1YearDuration7545000000JPY
Profit loss attributable to owners of parentCurrentYearDuration5101000000JPY
Profit lossPrior1YearDuration7545000000JPY
Profit lossCurrentYearDuration5101000000JPY
Valuation difference on available for sale securities net of tax ociPrior1YearDuration202000000JPY
Valuation difference on available for sale securities net of tax ociCurrentYearDuration60000000JPY
Remeasurements of defined benefit plans net of tax ociPrior1YearDuration362000000JPY
Remeasurements of defined benefit plans net of tax ociCurrentYearDuration-167000000JPY
Share of other comprehensive income of associates accounted for using equity method ociPrior1YearDuration16000000JPY
Share of other comprehensive income of associates accounted for using equity method ociCurrentYearDuration228000000JPY
Other comprehensive incomePrior1YearDuration581000000JPY
Other comprehensive incomeCurrentYearDuration121000000JPY
Comprehensive incomePrior1YearDuration8127000000JPY
Comprehensive incomeCurrentYearDuration5222000000JPY
Comprehensive income attributable to owners of the parentPrior1YearDuration8127000000JPY
Comprehensive income attributable to owners of the parentCurrentYearDuration5222000000JPY
Net assetsPrior2YearInstant_CapitalStockMember1197000000JPY
Net assetsPrior2YearInstant_CapitalSurplusMember1847000000JPY
Net assetsPrior2YearInstant_RetainedEarningsMember49619000000JPY
Net assetsPrior2YearInstant_TreasuryStockMember-3350000000JPY
Net assetsPrior2YearInstant_ShareholdersEquityMember49315000000JPY
Dividends from surplusPrior1YearDuration_RetainedEarningsMember-792000000JPY
Dividends from surplusPrior1YearDuration_ShareholdersEquityMember-792000000JPY
Profit loss attributable to owners of parentPrior1YearDuration_RetainedEarningsMember7545000000JPY
Profit loss attributable to owners of parentPrior1YearDuration_ShareholdersEquityMember7545000000JPY
Purchase of treasury stockPrior1YearDuration_TreasuryStockMember-0JPY
Purchase of treasury stockPrior1YearDuration_ShareholdersEquityMember-0JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 24 of 24 passed
balance sheet identityconsolidated 2024-03-31pass
balance sheet identityconsolidated 2025-03-31pass
balance sheet identitynon_consolidated 2024-03-31pass
balance sheet identitynon_consolidated 2025-03-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net assetsconsolidated 2025-03-31pass
statement vs summary · net assetsnon_consolidated 2023-03-31pass
statement vs summary · net assetsnon_consolidated 2024-03-31pass
statement vs summary · net assetsnon_consolidated 2025-03-31pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2024-03-31pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2025-03-31pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2024-03-31pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2025-03-31pass
statement vs summary · revenueconsolidated 2023-04-01/2024-03-31pass
statement vs summary · revenueconsolidated 2024-04-01/2025-03-31pass
statement vs summary · revenuenon_consolidated 2023-04-01/2024-03-31pass
statement vs summary · revenuenon_consolidated 2024-04-01/2025-03-31pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2025-03-31pass
statement vs summary · total assetsnon_consolidated 2024-03-31pass
statement vs summary · total assetsnon_consolidated 2025-03-31pass